Bausch + Lomb to Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

Bausch + Lomb announced one podium presentation and four poster presentations during the American Academy of Optometry (AAOpt) annual meeting, which will take place in New Orleans, October 11-14, 2023.

The podium presentation will highlight the results of a prospective, multicenter study that evaluated key clinical dry eye disease (DED) findings in patients using Blink Triple Care Dry Eye Lubricating Eye Drops. Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year for $106.5 million in cash.

Two poster presentations will include data on the newly launched Miebo prescription eye drops, including an evaluation of the distribution and retention of Miebo on the human eye and an analysis of the effect of Miebo on fluorescein staining across all regions of the cornea. Additionally, two posters will feature data on Bausch + Lomb INFUSE Multifocal silicone hydrogel daily disposable contact lenses, which launched in June, including an evaluation of the lens’ clinical performance and an assessment of patient responses to the lens.

Bausch + Lomb will also host several educational events during the meeting featuring Miebo eye drops, the new Lumify Eye Illuminations product line, Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, and Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%. Another educational event will highlight practical patient cases using products from across the company’s consumer, vision care and pharmaceutical portfolios.

The Bausch + Lomb schedule at AAOpt:

Podium Presentation

• “Clinical Dry Eye Findings in Patients Using a Novel Lipid-Containing Eye Drop.” Joshi et al.

Poster Presentations

• “Clinical Performance of a Novel Daily Disposable Silicone Hydrogel Multifocal Contact Lens.” Schafer et al.
• “Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Reduces Corneal Staining Across All Regions of the Cornea.” Fahmy et al.
• “Presbyopic Patient Assessment of a New Daily Disposable Silicone Hydrogel Multifocal Contact Lens.” Rah et al.
• “Visualization of Miebo, an Eye Drop for Dry Eye Disease, on the Human Ocular Surface Using Infrared Emisivity.” Borchman et al.

Featured Educational Events

Wednesday, October 11

• “Industry Innovation Lunch and Learn”
  12-12:55 p.m. CT at the Ernest N. Morial Convention Center (900 Convention Center Blvd., New Orleans; Room R06, second floor)
  Gina Wesley, O.D., John Womack, O.D., and Doug DeVries, O.D., will share practical patient cases using products from across the Bausch + Lomb consumer, vision care and pharmaceutical portfolios.

• “Showcasing Inflammation and IOP Control”
  6:45 p.m. CT at Palace Café (605 Canal Street, New Orleans; room Fleur de Lis)
  Michael Chaglasian, O.D., and Nora Cothran, O.D. will discuss the benefits of using Lotemax SM (loteprednol etabonate ophthalmic gel), 0.38%, and Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%. Register in advance.

Thursday, October 12

• “Introducing New Lumify Eye Illuminations”
  8:00-8:45 a.m. CT at Hilton New Orleans Riverside (Two Poydras Street, New Orleans; room Royal)
  Join Gina Wesley, O.D., to discover Lumify Eye Illuminations, a new specialty eye care line.

• “Innovations in Inflammation and IOP Control”
  8:00-8:45 a.m. CT at Hilton New Orleans Riverside (Two Poydras Street, New Orleans; room Camp)
  Derek Cunningham, O.D., will discuss the benefits of using Lotemax SM (loteprednol etabonate ophthalmic gel), 0.38%, and Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%.

• “Fighting the Battle in the Rx Treatment of Evaporative Dry Eye Disease: Introducing Miebo (Perfluorohexyloctane Ophthalmic Solution)”
  6:00 p.m. CT at the National World War II Museum (1043 Magazine Street, US Freedom Pavilion, New Orleans)
  Learn about Miebo, the first and only prescription eye drop that directly targets tear evaporation, as well as the results of the MIEBO pivotal phase 3 studies. Register in advance.

Friday, October 13

• “Miebo (perfluorohexyloctane ophthalmic solution): A Newly Approved Product”
  8:00-8:45 a.m. CT at Hilton New Orleans Riverside Hotel (Two Poydras Street, New Orleans; room Canal)
  Tear evaporation is the leading cause of dry eye disease. Join James Deom, O.D., to learn more about Miebo, the first and only prescription eye drop that directly addresses tear evaporation.

• “A New Orleans Nightcap with Lumify Eye Illuminations”
  8:30-10:30 p.m. CT at the Gallery Venue (755 Tchoupitoulas Street, New Orleans)
  Celebrate the launch of Lumify Eye Illuminations and learn about these new clinically proven products from Selina McGee, O.D. Register in advance.